0001426332 2022-01-01 2022-12-31 0001426332 2023-02-22 0001426332 2022-06-30 shares iso4217:USD true FY 0001426332 10-K/A true 2022-12-31 --12-31 2022 false 001-38853 NGM BIOPHARMACEUTICALS, INC. DE 26-1679911 333 Oyster Point Boulevard South San Francisco CA 94080 650 243-5555 Common Stock, par value $0.001 per share NGM NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 699000000 82046499 42 Ernst & Young LLP San Mateo, California Portions of the registrant’s definitive Proxy Statement for the 2023 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form <div style="white-space:nowrap;display:inline;">10-K</div> are incorporated by reference in Part III, Items <div style="white-space:nowrap;display:inline;">10-14</div> of this Annual Report on Form <div style="white-space:nowrap;display:inline;">10-K.</div> NGM Biopharmaceuticals, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission (the “SEC”) on February 28, 2023 (the “Original Filing”) to correct an inadvertent error that was included in Exhibit 31.2 to the Original Filing. In the version of Exhibit 31.2 filed with the Original Filing, the phrase “and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))” was inadvertently omitted from the introductory language in Section 4 of such exhibit. The Company is filing this Amendment solely for the purpose of correcting the text of the certification contained in Exhibit 31.2 of the Original Filing. No attempt has been made in this Amendment to otherwise modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the Original Filing (i.e., those events occurring after February 28, 2023) or modify or update those disclosures that may be affected by subsequent events. Such subsequent matters are addressed in subsequent reports filed with the SEC. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company’s other filings with the SEC.